If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

Dr. David Boulware is an infectious disease physician-scientist with formal training in public health, clinical trials, and tropical medicine.  As a translational researcher, Dr. Boulware combines his clinical research training with basic science investigations into disease pathogenesis. His primary research interests are in meningitis in resource-limited areas including diagnosis, prevention, treatment, and quality improvement initiatives incorporating cost-effectiveness analyses in order to translate knowledge into improved care.

Dr. Boulware’s current research is focused on improving the clinical outcomes of HIV-infected persons with meningitis.  Cryptococcal meningitis is the second most common AIDS-defining opportunistic infection in Sub-Saharan Africa and the most common cause of adult meningitis. Why Cryptococcus?  During 2016, cryptococcal meningitis accounts for ~70% of adult meningitis in Uganda. Even in the U.S., the estimated incidence of 1.1 hospitalizations for cryptococcal meningitis makes this more common than all causes of bacterial meningitis combined. Prevention with targeted cryptococcal antigen screening and preemptive therapy for early disseminated Cryptococcus infection is of great interest with ongoing clinical studies and trials. Diagnostics for TB meningitis have become an emerging area of interest and research.  Dr. Boulware has active research collaborations in Uganda, South Africa, Tanzania, and Ethiopia leading a multidisciplinary, international research team which is highly collaborative in working with others.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 7 Similar Profiles
Cryptococcal Meningitis Medicine & Life Sciences
HIV Medicine & Life Sciences
Cerebrospinal Fluid Medicine & Life Sciences
Immune Reconstitution Inflammatory Syndrome Medicine & Life Sciences
Uganda Medicine & Life Sciences
Meningeal Tuberculosis Medicine & Life Sciences
Antigens Medicine & Life Sciences
Meningitis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2009 2023

Research Output 2003 2019

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: Economic evaluation protocol for a randomised controlled trial-based equivalence study

Ponatshego, P. L., Lawrence, D. S., Youssouf, N., Molloy, S. F., Alufandika, M., Bango, F., Boulware, D. R., Chawinga, C., Dziwani, E., Gondwe, E., Hlupeni, A., Hosseinipour, M. C., Kanyama, C., Meya, D. B., Mosepele, M., Muthoga, C., Muzoora, C. K., Mwandumba, H., Ndhlovu, C. E., Rajasingham, R. & 18 othersSayed, S., Shamu, S., Tsholo, K., Tugume, L., Williams, D., Maheswaran, H., Shiri, T., Boyer-Chammard, T., Loyse, A., Chen, T., Wang, D., Lortholary, O., Lalloo, D. G., Meintjes, G., Jaffar, S., Harrison, T. S., Jarvis, J. N. & Niessen, L. W., Apr 1 2019, In : BMJ open. 9, 4, e026288.

Research output: Contribution to journalArticle

Cryptococcal Meningitis
Africa South of the Sahara
Cost-Benefit Analysis
Randomized Controlled Trials
Amphotericin B

Case report: Three's a crowd: A case report examining the diagnostic and pharmacokinetic challenges in hiv-tuberculous meningitis-malaria co-infection [version 2; referees: 2 approved]

Ellis, J., Eneh, P. C., Ssebambulidde, K., Rutakingirwa, M. K., Lamorde, M., Rhein, J. R., Cresswell, F. V., Boulware, D. R. & Nicol, M. R., Jan 1 2019, In : Wellcome Open Research. 3, 111.

Research output: Contribution to journalArticle

Open Access
Meningeal Tuberculosis
Pharmacokinetics
Rifampin
Coinfection
Malaria

Correction: AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: Study protocol for a phase 3 randomised controlled non-inferiority trial (Trials (2018) 19 (649) DOI: 10.1186/s13063-018-3026-4)

Lawrence, D. S., Youssouf, N., Molloy, S. F., Alanio, A., Alufandika, M., Boulware, D. R., Boyer-Chammard, T., Chen, T., Dromer, F., Hlupeni, A., Hope, W., Hosseinipour, M. C., Kanyama, C., Lortholary, O., Loyse, A., Meya, D. B., Mosepele, M., Muzoora, C., Mwandumba, H. C., Ndhlovu, C. E. & 9 othersNiessen, L., Schutz, C., Stott, K. E., Wang, D., Lalloo, D. G., Meintjes, G., Jaffar, S., Harrison, T. S. & Jarvis, J. N., Jan 14 2019, In : Trials. 20, 1, 48.

Research output: Contribution to journalComment/debate

Open Access
Cryptococcal Meningitis
Africa South of the Sahara
Names
Publications
Therapeutics

Cryptococcal meningitis diagnostics and screening in the era of point-of-care laboratory testing

Rajasingham, R., Wake, R. M., Beyene, T., Katende, A., Letang, E. & Boulware, D. R., Jan 1 2019, In : Journal of clinical microbiology. 57, 1, e01238.

Research output: Contribution to journalReview article

Cryptococcal Meningitis
Antigens
Meningitis
Point-of-Care Systems
HIV Antigens

Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodies

Bahr, N. C., Panackal, A. A., Durkin, M. M., Smedema, M. L., Keown, W., Davis, T. E., Raymond-Guillen, L., Park, Y. D., Marr, K. A., Fries, B. C., Williamson, P. R., Boulware, D. R. & Wheat, L. J., Jan 1 2019, (Accepted/In press) In : Mycoses.

Research output: Contribution to journalArticle

Blastomyces
Coccidioides
Cryptococcal Meningitis
Histoplasma
Cerebrospinal Fluid